Sai Parenterals Limited has submitted to the Exchange, the financial results for the period ended March 31, 2026.
SAIPARENT · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Sai Parenterals Limited reported strong audited financial results for FY 2025-26. Standalone revenue grew 69% to Rs 1,242.69 crore from Rs 735.84 crore in the previous year. Profit after tax increased 63% to Rs 167.77 crore from Rs 102.83 crore. The company filed a Draft Red Herring Prospectus (DRHP) for its proposed IPO during the period. Statutory auditors R Kabra & Co. LLP issued an unmodified (clean) audit opinion. The company completed acquisition of 74.64% controlling stake in Noumed Life Sciences Limited (UK) for AUD 22 million through its Singapore subsidiary. Total assets on standalone basis grew from Rs 2,149.66 crore to Rs 8,039.79 crore, reflecting significant expansion including the acquisition.
Positive signal for investors with strong revenue and profit growth. However, debt levels increased significantly (total borrowings at Rs 1,332.06 crore standalone) and the company is yet to be listed, with IPO pending.